Browse CNTNAP2

Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein Cell projection, axon Cell junction, paranodal septate junction Note=Expressed in the juxtaparadonal region.
Domain PF00754 F5/8 type C domain
PF02210 Laminin G domain
Function

Required, with CNTNAP1, for radial and longitudinal organization of myelinated axons. Plays a role in the formation of functional distinct domains critical for saltatory conduction of nerve impulses in myelinated nerve fibers. Demarcates the juxtaparanodal region of the axo-glial junction.

> Gene Ontology
 
Biological Process GO:0007611 learning or memory
GO:0007612 learning
GO:0007638 mechanosensory behavior
GO:0008037 cell recognition
GO:0008038 neuron recognition
GO:0009612 response to mechanical stimulus
GO:0010996 response to auditory stimulus
GO:0019226 transmission of nerve impulse
GO:0021536 diencephalon development
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021544 subpallium development
GO:0021700 developmental maturation
GO:0021756 striatum development
GO:0021761 limbic system development
GO:0021794 thalamus development
GO:0021987 cerebral cortex development
GO:0030534 adult behavior
GO:0030900 forebrain development
GO:0031223 auditory behavior
GO:0035176 social behavior
GO:0035637 multicellular organismal signaling
GO:0042297 vocal learning
GO:0042551 neuron maturation
GO:0044708 single-organism behavior
GO:0045161 neuronal ion channel clustering
GO:0045163 clustering of voltage-gated potassium channels
GO:0048469 cell maturation
GO:0050890 cognition
GO:0051703 intraspecies interaction between organisms
GO:0051705 multi-organism behavior
GO:0071109 superior temporal gyrus development
GO:0071205 protein localization to juxtaparanode region of axon
GO:0071625 vocalization behavior
GO:0098596 imitative learning
GO:0098597 observational learning
GO:0098598 learned vocalization behavior or vocal learning
GO:0099612 protein localization to axon
Molecular Function -
Cellular Component GO:0005769 early endosome
GO:0008076 voltage-gated potassium channel complex
GO:0030424 axon
GO:0030425 dendrite
GO:0030673 axolemma
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0032589 neuron projection membrane
GO:0033267 axon part
GO:0034702 ion channel complex
GO:0034703 cation channel complex
GO:0034705 potassium channel complex
GO:0043025 neuronal cell body
GO:0043204 perikaryon
GO:0044224 juxtaparanode region of axon
GO:0044297 cell body
GO:0044304 main axon
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
Reactome -
Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CNTNAP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CNTNAP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CNTNAP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3940.472
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0630.41
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4440.758
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7480.324
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6730.605
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7010.587
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9120.113
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8660.0104
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5020.156
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CNTNAP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277329.69.6200.0237
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275929.611.917.70.065
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211733.311.821.50.148
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131138.518.220.30.386
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382718.47.4110.285
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614257.117.90.336
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CNTNAP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CNTNAP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CNTNAP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CNTNAP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CNTNAP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CNTNAP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCNTNAP2
Namecontactin associated protein-like 2
Aliases Caspr2; KIAA0868; AUTS15; CDFE; PTHSL1; cell recognition molecule Caspr2; homolog of Drosophila neurexin IV; ......
Chromosomal Location7q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CNTNAP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.